ClinicalTrials.gg
CompletedNCT05018806Updated Jul 13, 2026Results posted

Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis

A Phase 2 interventional study of Placebo and Rilzabrutinib in Atopic Dermatitis, sponsored by Sanofi. Completed at 31 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Dermatitis, Atopic by Sanofi — 5 open to participants now, 16 under way, 4 of them phase 3. Dermatitis, Atopic · Sanofi.

Enrollment
14th of 28
124 · median 112
Started
2021
with 5 others
Phase 2
8 of 43
none open now
Registered
14th of 43
by date

Among the 43 studies in Dermatitis, Atopic by Sanofi, this one is the 14th largest by enrollment of the 28 interventional ones that give a count, is one of 6 that started in 2021, is one of 8 in phase 2, and was the 14th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

5 of the 43 studies in Dermatitis, Atopic by Sanofi are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Dermatitis, Atopic by Sanofi, or all of them as a file.
02

Study summary

This was a parallel treatment, Phase 2, double-blind, 2-arm, placebo-controlled study with 2 staggered cohorts (2 arms in each cohort) to evaluate the efficacy and safety of rilzabrutinib in adult participants (aged at least 18 years) with moderate-to-severe AD and intolerance or inadequate response to topical corticosteroids (TCS).

The total study duration per participant was expected to be approximately 21 weeks, including up to 4 weeks of screening, 16 weeks of on-treatment double-blind period, 1 week of post-treatment follow-up.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • AD as defined by the American Academy of Dermatology Consensus Criteria.
  • History of AD for at least 12 months prior to baseline as determined by the Investigator through patient interview.
  • Eczema Area and Severity Index (EASI) score ≥ 12 at screening and at baseline.
  • IGA score ≥ 3 (on the 0 to 4 IGA scale) at baseline.
  • BSA of AD involvement ≥ 10% at baseline.
  • Documented inadequate response or intolerance to TCS within 6 months prior to baseline visit
  • Baseline PP-NRS score for maximum itch intensity ≥4.
  • All use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • For optional substudy only: Willingness to have 2 tape strips for comparison of baseline and treatment response.

Exclusion criteria

Exclusion Criteria:

  • Skin comorbidities that may interfere with study assessments such as psoriasis, tinea corporis, lupus erythematosus.
  • Conditions that may predispose the patient to excessive bleeding.
  • Any other disease, condition, or medical history that, in the opinion of the Investigator, would interfere with participant safety, trial evaluations, and/or trial procedures.
  • Laboratory abnormalities at the screening visit
  • History of serious infections requiring intravenous therapy with the potential for recurrence (as judged by the Site Investigator and the Sponsor Medical Monitor), with less than 4 weeks interval between resolution of serious infection and first dose of study drug, or currently active moderate to severe infection at Screening (Grade 2 or higher) including active coronavirus disease 2019 (COVID-19).
  • except Bacille Calmette Guerin-vaccination within 28 days prior to Day 1 or plan to receive one during the trial; Bacille Calmette Guerin-vaccination within 12 months prior to Screening.
  • COVID-19 vaccine within 14 days prior to Study Day 1.
  • nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate rilzabrutinib/placebo absorption.
  • Initiation of prescription moisturizers (with or without additives such as ceramide, hyaluronic acid, urea, or filaggrin), topical anesthetics or antihistamines during the screening period.
  • Use of TCS, topical calcineurin (tacrolimus, and/or pimecrolimus) or topical phosphodiesterase 4 inhibitor within 1 week prior to baseline and as concomitant medication.
  • Use of systemic within 4 weeks prior to baseline and as concomitant medication.
  • Phototherapy for AD or regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks prior to baseline or likely to be required as concomitant procedure during the study.
  • Use of mycophenolate mofetil, azathioprine, methotrexate, cyclosporine, dapsone, intravenous immunoglobulin (IVIG), Kineret (anakinra), Enbrel (etanercept), or any other not mentioned in this exclusion criterion within 4 weeks prior to baseline.
  • Use of infliximab, adalimumab, golimumab, abatacept, tocilizumab, certolizumab, secukinumab, IFN-γ, JAK inhibitors, dupilumab, and any other biologic or targeted-synthetic disease modifier drug not mentioned in this exclusion criterion or in exclusion criterion, as well as plasmapheresis within 12 weeks prior to baseline.
  • Use of anti-CD20 drugs such as rituximab, ofatumumab, other long-acting biologics within 6 months prior to baseline (or shorter if there is documented B cell reconstitution for anti-CD20 drugs).
  • Use of proton pump inhibitor drugs such as omeprazole and esomeprazole within 3 days of baseline (it is acceptable to change participant to H2 receptor blocking drugs prior to baseline).
  • Concomitant use of known systemic strong-to-moderate inhibitors and inducers of cytochrome P450 3A () within 14 days or 5 half-lives (whichever is longer) prior to baseline.
  • Previous use of a BTK inhibitor.
  • Had received any drug (or is currently using an investigational device) within the 30 days before baseline, or at least 5 times the respective elimination half-life time (whichever is longer).
  • Active TB or a history of incompletely treated TB, Quantiferon positive patients, Clinically significant abnormality consistent with prior/active TB infection based upon chest radiograph with at least posterior-anterior view, Suspected extrapulmonary TB infection, or patients at high risk of contracting TB.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
124 participants (actual)

Study arms

  • Placebo comparator
    BID cohort: Placebo

    Participants received placebo matched to rilzabrutinib orally BID from Day 1 up to Week 16. Consecutive doses were ideally administered 12 hours apart (and not less than 8 hours apart).

    Drug: Placebo

  • Experimental
    BID cohort: Rilzabrutinib

    Participants received rilzabrutinib 400 milligrams (mg) orally BID from Day 1 up to Week 16. Consecutive doses were ideally administered 12 hours apart (and not less than 8 hours apart).

    Drug: Rilzabrutinib

  • Placebo comparator
    TID cohort: Placebo

    Participants received placebo matched to rilzabrutinib orally TID from Day 1 up to Week 16. Consecutive doses were ideally administered at least 6 hours apart (and not less than 4 hours apart).

    Drug: Placebo

  • Experimental
    TID cohort: Rilzabrutinib

    Participants received rilzabrutinib 400 mg orally TID from Day 1 up to Week 16. Consecutive doses were ideally administered at least 6 hours apart (and not less than 4 hours apart).

    Drug: Rilzabrutinib

Interventions

  • DrugPlacebo

    Pharmaceutical form: Tablet Route of administration: Oral

  • Pharmaceutical form: Tablet Route of administration: Oral

    Also known as: PRN1008/SAR444671

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score

    The EASI index is a validated investigator-administered scoring system used to measure the severity of clinical signs in atopic dermatitis (AD). Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) were each assessed for severity by the investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement were assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. 0: 0% of body surface area (BSA) involvement with AD; 1: 1-9%; 2: 10-29%; 2: 30-49%; 4: 50-69%; 5: 70-89% and 6: 90-100% of BSA involvement with AD. Total score ranged from 0 (minimum) to 72 (maximum); higher scores indicated greater severity of AD. Baseline was defined as the Day 1 assessment value.

    Time frame: Baseline (Day 1) to Week 16

Secondary outcomes

  1. Percentage of Participants With Investigator's Global Assessment (IGA) of 0 or 1 At Week 16

    IGA is a static 5-point measure of disease severity based on an overall assessment of the skin lesions on a 5-point scale (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease). Higher score indicated higher severity.

    Time frame: Week 16

  2. Percentage of Participants Achieving EASI-75 (Reduction of EASI Score By ≥75% From Baseline) At Week 16

    The EASI index is a validated investigator-administered scoring system used to measure the severity of clinical signs in AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) were each assessed for severity by the investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement were assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. 0: 0% of BSA involvement with AD; 1: 1-9%; 2: 10-29%; 2: 30-49%; 4: 50-69%; 5: 70-89% and 6: 90-100% of BSA involvement with AD. Total score ranged from 0 (minimum) to 72 (maximum); higher scores indicated greater severity of AD. Participants who achieved EASI-75 were defined as participants with reduction of EASI score by ≥75% from baseline.

    Time frame: Baseline (Day 1) and at Week 16

  3. Percentage Of Participants With Reduction of Weekly Average of Daily Peak Pruritus Numerical Rating Scale (PP-NRS) of ≥4 Points From Baseline at Week 16

    The PP-NRS is a simple assessment tool that participants used to report the intensity of their pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 (no itch) to 10 (worst itch imaginable) NRS by answering the following question: For itch intensity, "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". The total score on the scale ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse symptoms. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score.

    Time frame: Baseline (Day 1) and at Week 16

  4. Number of Participants With Weekly Average of Daily PP-NRS Reduction ≥4 From Baseline During The 16-Week Treatment Period

    The PP-NRS is a simple assessment tool that participants used to report the intensity of their pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 (no itch) to 10 (worst itch imaginable) NRS by answering the following question: For itch intensity, "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". The total score on the scale ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse symptoms. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score.

    Time frame: Baseline (Day 1) and Week 16

  5. Absolute Change From Baseline to Week 16 In EASI Score

    The EASI index is a validated investigator-administered scoring system used to measure the severity of clinical signs in AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) were each assessed for severity by the investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement were assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. 0: 0% of BSA involvement with AD; 1: 1-9%; 2: 10-29%; 2: 30-49%; 4: 50-69%; 5: 70-89% and 6: 90-100% of BSA involvement with AD. Total score ranged from 0 (minimum) to 72 (maximum); higher scores indicated greater severity of AD. Baseline was defined as the Day 1 assessment value.

    Time frame: Baseline (Day 1) to Week 16

  6. Percentage of Participants Achieving EASI-50/90 (Reduction of EASI Score by ≥50% or ≥90% From Baseline) at Week 16

    The EASI index is a validated investigator-administered scoring system used to measure the severity of clinical signs in AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) were each assessed for severity by the investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement were assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. 0: 0% of BSA involvement with AD; 1: 1-9%; 2: 10-29%; 2: 30-49%; 4: 50-69%; 5: 70-89% and 6: 90-100% of BSA involvement with AD. Total score ranged from 0 (minimum) to 72 (maximum); higher scores indicated greater severity of AD. Participants who achieved EASI-50/90 were defined as participants with reduction of EASI score by ≥50% or ≥90% from baseline respectively.

    Time frame: Baseline (Day 1) and at Week 16

  7. Change From Baseline to Week 16 in Percent BSA of AD

    BSA affected by AD were assessed for each section of the body (the possible highest score for each region was: head and neck \[10%\], trunk including genitalia \[30%\], upper limbs \[20%\], lower limbs \[40%\]) and were reported as a percentage of all major body sections combined. Total score ranges from 0% to 100%. The higher score indicates a worse value and a lower score indicates a better value. Baseline was defined as the Day 1 assessment value.

    Time frame: Baseline (Day 1) to Week 16

  8. Absolute Change From Baseline to Week 16 in Weekly Average of Daily PP-NRS

    The PP-NRS is a simple assessment tool that participants used to report the intensity of their pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 (no itch) to 10 (worst itch imaginable) NRS by answering the following question: For itch intensity, "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". The total score on the scale ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse symptoms. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score. Baseline was defined as the Day 1 assessment value.

    Time frame: Baseline (Day 1) to Week 16

  9. Percent Change From Baseline to Week 16 in Weekly Average of Daily PP-NRS

    The PP-NRS is a simple assessment tool that participants used to report the intensity of their pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 (no itch) to 10 (worst itch imaginable) NRS by answering the following question: For itch intensity, "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". The total score on the scale ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse symptoms. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score. Baseline was defined as the Day 1 assessment value.

    Time frame: Baseline (Day 1) to Week 16

  10. Percentage of Participants Achieving IGA*BSA-50/75/90 (Reduction of IGA*BSA by ≥50% or 75% or 90% From Baseline) At Week 16

    IGA is a static 5-point measure of disease severity based on an overall assessment of the skin lesions on a 5-point scale (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease). Higher score indicated higher severity. Participants who achieved IGA\*BSA-50-75-90 were defined as participants with reduction of IGA\*BSA by ≥50% or 75% or 90% from baseline.

    Time frame: Baseline (Day 1) and at Week 16

  11. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Adverse Events of Special Interest (AESIs) and Study Intervention Discontinuation

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as AEs that developed, worsened or became serious during the treatment-emergent period. SAE was any AE that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required.

    Time frame: Baseline (Day 1) to 16 weeks

07

Results

Posted Jul 13, 2026

Participant flow

The study was conducted at 31 centers in 7 countries. 61 participants in twice a day (BID) cohort and 106 participants in three times a day (TID) cohort were screened from 09 September 2021 to 24 February 2023, of which 16 in BID cohort and 27 in TID cohort were screen failures. Screen failures were mainly due to not meeting the eligibility criteria.

Participant flow — Overall Study
MilestoneBID Cohort: PlaceboBID Cohort: Rilzabrutinib 400 mg BIDTID Cohort: PlaceboTID Cohort: Rilzabrutinib 400 mg TID
Started18273148
Completed14232631
Not completed44517
Withdrew: Adverse event (ae): not related to coronavirus disease-2019 (covid-19)1127
Withdrew: Withdrawal by subject33310

Outcome measures

PrimaryPercent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score

The EASI index is a validated investigator-administered scoring system used to measure the severity of clinical signs in atopic dermatitis (AD). Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) were each assessed for severity by the investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement were assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. 0: 0% of body surface area (BSA) involvement with AD; 1: 1-9%; 2: 10-29%; 2: 30-49%; 4: 50-69%; 5: 70-89% and 6: 90-100% of BSA involvement with AD. Total score ranged from 0 (minimum) to 72 (maximum); higher scores indicated greater severity of AD. Baseline was defined as the Day 1 assessment value.

Time frame:
Baseline (Day 1) to Week 16
Reported as:
Least squares mean · Percent change
Percent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score
Percent changeBID Cohort: PlaceboBID Cohort: RilzabrutinibTID Cohort: PlaceboTID Cohort: Rilzabrutinib
Percent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score-47.33 ± 9.77-53.57 ± 8.25-43.33 ± 6.99-47.21 ± 6.26
Statistical analysis
  • BID Cohort: Placebo vs BID Cohort: Rilzabrutinib · ANCOVA · p = 0.6246 · Least square mean difference: -6.25 · 95% CI -31.26 to 18.77
  • TID Cohort: Placebo vs TID Cohort: Rilzabrutinib · ANCOVA · p = 0.6740 · Least square mean difference: -3.88 · 95% CI -21.97 to 14.21
SecondaryPercentage of Participants With Investigator's Global Assessment (IGA) of 0 or 1 At Week 16

IGA is a static 5-point measure of disease severity based on an overall assessment of the skin lesions on a 5-point scale (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease). Higher score indicated higher severity.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Investigator's Global Assessment (IGA) of 0 or 1 At Week 16
Percentage of participantsBID Cohort: PlaceboBID Cohort: RilzabrutinibTID Cohort: PlaceboTID Cohort: Rilzabrutinib
Percentage of Participants With Investigator's Global Assessment (IGA) of 0 or 1 At Week 1622.27.412.914.6
SecondaryPercentage of Participants Achieving EASI-75 (Reduction of EASI Score By ≥75% From Baseline) At Week 16

The EASI index is a validated investigator-administered scoring system used to measure the severity of clinical signs in AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) were each assessed for severity by the investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement were assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. 0: 0% of BSA involvement with AD; 1: 1-9%; 2: 10-29%; 2: 30-49%; 4: 50-69%; 5: 70-89% and 6: 90-100% of BSA involvement with AD. Total score ranged from 0 (minimum) to 72 (maximum); higher scores indicated greater severity of AD. Participants who achieved EASI-75 were defined as participants with reduction of EASI score by ≥75% from baseline.

Time frame:
Baseline (Day 1) and at Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving EASI-75 (Reduction of EASI Score By ≥75% From Baseline) At Week 16
Percentage of participantsBID Cohort: PlaceboBID Cohort: RilzabrutinibTID Cohort: PlaceboTID Cohort: Rilzabrutinib
Percentage of Participants Achieving EASI-75 (Reduction of EASI Score By ≥75% From Baseline) At Week 1627.829.629.018.8
SecondaryPercentage Of Participants With Reduction of Weekly Average of Daily Peak Pruritus Numerical Rating Scale (PP-NRS) of ≥4 Points From Baseline at Week 16

The PP-NRS is a simple assessment tool that participants used to report the intensity of their pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 (no itch) to 10 (worst itch imaginable) NRS by answering the following question: For itch intensity, "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". The total score on the scale ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse symptoms. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score.

Time frame:
Baseline (Day 1) and at Week 16
Reported as:
Number · Percentage of participants
Percentage Of Participants With Reduction of Weekly Average of Daily Peak Pruritus Numerical Rating Scale (PP-NRS) of ≥4 Points From Baseline at Week 16
Percentage of participantsBID Cohort: PlaceboBID Cohort: RilzabrutinibTID Cohort: PlaceboTID Cohort: Rilzabrutinib
Percentage Of Participants With Reduction of Weekly Average of Daily Peak Pruritus Numerical Rating Scale (PP-NRS) of ≥4 Points From Baseline at Week 1611.118.512.920.8
SecondaryNumber of Participants With Weekly Average of Daily PP-NRS Reduction ≥4 From Baseline During The 16-Week Treatment Period

The PP-NRS is a simple assessment tool that participants used to report the intensity of their pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 (no itch) to 10 (worst itch imaginable) NRS by answering the following question: For itch intensity, "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". The total score on the scale ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse symptoms. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Count of participants · Participants
Number of Participants With Weekly Average of Daily PP-NRS Reduction ≥4 From Baseline During The 16-Week Treatment Period
ParticipantsBID Cohort: PlaceboBID Cohort: RilzabrutinibTID Cohort: PlaceboTID Cohort: Rilzabrutinib
Number of Participants With Weekly Average of Daily PP-NRS Reduction ≥4 From Baseline During The 16-Week Treatment Period27413
SecondaryAbsolute Change From Baseline to Week 16 In EASI Score

The EASI index is a validated investigator-administered scoring system used to measure the severity of clinical signs in AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) were each assessed for severity by the investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement were assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. 0: 0% of BSA involvement with AD; 1: 1-9%; 2: 10-29%; 2: 30-49%; 4: 50-69%; 5: 70-89% and 6: 90-100% of BSA involvement with AD. Total score ranged from 0 (minimum) to 72 (maximum); higher scores indicated greater severity of AD. Baseline was defined as the Day 1 assessment value.

Time frame:
Baseline (Day 1) to Week 16
Reported as:
Least squares mean · Scores on a scale
Absolute Change From Baseline to Week 16 In EASI Score
Scores on a scaleBID Cohort: PlaceboBID Cohort: RilzabrutinibTID Cohort: PlaceboTID Cohort: Rilzabrutinib
Absolute Change From Baseline to Week 16 In EASI Score-12.83 ± 2.31-14.00 ± 1.94-10.37 ± 2.48-11.34 ± 2.20
SecondaryPercentage of Participants Achieving EASI-50/90 (Reduction of EASI Score by ≥50% or ≥90% From Baseline) at Week 16

The EASI index is a validated investigator-administered scoring system used to measure the severity of clinical signs in AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) were each assessed for severity by the investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement were assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. 0: 0% of BSA involvement with AD; 1: 1-9%; 2: 10-29%; 2: 30-49%; 4: 50-69%; 5: 70-89% and 6: 90-100% of BSA involvement with AD. Total score ranged from 0 (minimum) to 72 (maximum); higher scores indicated greater severity of AD. Participants who achieved EASI-50/90 were defined as participants with reduction of EASI score by ≥50% or ≥90% from baseline respectively.

Time frame:
Baseline (Day 1) and at Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving EASI-50/90 (Reduction of EASI Score by ≥50% or ≥90% From Baseline) at Week 16
Percentage of participantsBID Cohort: PlaceboBID Cohort: RilzabrutinibTID Cohort: PlaceboTID Cohort: Rilzabrutinib
EASI-5055.644.438.729.2
EASI-9016.711.112.98.3
SecondaryChange From Baseline to Week 16 in Percent BSA of AD

BSA affected by AD were assessed for each section of the body (the possible highest score for each region was: head and neck \[10%\], trunk including genitalia \[30%\], upper limbs \[20%\], lower limbs \[40%\]) and were reported as a percentage of all major body sections combined. Total score ranges from 0% to 100%. The higher score indicates a worse value and a lower score indicates a better value. Baseline was defined as the Day 1 assessment value.

Time frame:
Baseline (Day 1) to Week 16
Reported as:
Least squares mean · Percent of body surface area
Change From Baseline to Week 16 in Percent BSA of AD
Percent of body surface areaBID Cohort: PlaceboBID Cohort: RilzabrutinibTID Cohort: PlaceboTID Cohort: Rilzabrutinib
Change From Baseline to Week 16 in Percent BSA of AD-10.45 ± 4.37-15.30 ± 3.61-7.35 ± 3.38-11.80 ± 3.08
SecondaryAbsolute Change From Baseline to Week 16 in Weekly Average of Daily PP-NRS

The PP-NRS is a simple assessment tool that participants used to report the intensity of their pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 (no itch) to 10 (worst itch imaginable) NRS by answering the following question: For itch intensity, "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". The total score on the scale ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse symptoms. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score. Baseline was defined as the Day 1 assessment value.

Time frame:
Baseline (Day 1) to Week 16
Reported as:
Least squares mean · Scores on a scale
Absolute Change From Baseline to Week 16 in Weekly Average of Daily PP-NRS
Scores on a scaleBID Cohort: PlaceboBID Cohort: RilzabrutinibTID Cohort: PlaceboTID Cohort: Rilzabrutinib
Absolute Change From Baseline to Week 16 in Weekly Average of Daily PP-NRS-1.60 ± 0.66-3.11 ± 0.52-0.83 ± 0.51-2.07 ± 0.43
SecondaryPercent Change From Baseline to Week 16 in Weekly Average of Daily PP-NRS

The PP-NRS is a simple assessment tool that participants used to report the intensity of their pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 (no itch) to 10 (worst itch imaginable) NRS by answering the following question: For itch intensity, "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". The total score on the scale ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse symptoms. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score. Baseline was defined as the Day 1 assessment value.

Time frame:
Baseline (Day 1) to Week 16
Reported as:
Least squares mean · Percent change
Percent Change From Baseline to Week 16 in Weekly Average of Daily PP-NRS
Percent changeBID Cohort: PlaceboBID Cohort: RilzabrutinibTID Cohort: PlaceboTID Cohort: Rilzabrutinib
Percent Change From Baseline to Week 16 in Weekly Average of Daily PP-NRS-21.55 ± 8.37-43.53 ± 6.80-10.36 ± 7.19-30.13 ± 6.08
SecondaryPercentage of Participants Achieving IGA*BSA-50/75/90 (Reduction of IGA*BSA by ≥50% or 75% or 90% From Baseline) At Week 16

IGA is a static 5-point measure of disease severity based on an overall assessment of the skin lesions on a 5-point scale (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease). Higher score indicated higher severity. Participants who achieved IGA\*BSA-50-75-90 were defined as participants with reduction of IGA\*BSA by ≥50% or 75% or 90% from baseline.

Time frame:
Baseline (Day 1) and at Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving IGA*BSA-50/75/90 (Reduction of IGA*BSA by ≥50% or 75% or 90% From Baseline) At Week 16
Percentage of participantsBID Cohort: PlaceboBID Cohort: RilzabrutinibTID Cohort: PlaceboTID Cohort: Rilzabrutinib
IGA*BSA-5038.940.738.729.2
IGA*BSA-7522.225.922.618.8
IGA*BSA-905.618.59.710.4
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Adverse Events of Special Interest (AESIs) and Study Intervention Discontinuation

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as AEs that developed, worsened or became serious during the treatment-emergent period. SAE was any AE that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required.

Time frame:
Baseline (Day 1) to 16 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Adverse Events of Special Interest (AESIs) and Study Intervention Discontinuation
ParticipantsBID Cohort: PlaceboBID Cohort: RilzabrutinibTID Cohort: PlaceboTID Cohort: Rilzabrutinib
TEAEs10151938
TESAEs0011
AESI3020
TEAEs leading to studyintervention discontinuation0229

Adverse events

Collected over TEAEs were collected from Baseline (Day 1) to 16 weeks. All-cause mortality (Deaths) was collected throughout the study, approximately 97 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BID Cohort: Placebo0/18 (0%)0/18 (0%)10/18 (55.6%)
BID Cohort: Rilzabrutinib 400 mg BID0/27 (0%)0/27 (0%)15/27 (55.6%)
TID Cohort: Placebo0/31 (0%)1/31 (3.2%)19/31 (61.3%)
TID Cohort: Rilzabrutinib 400 mg TID0/48 (0%)1/48 (2.1%)38/48 (79.2%)
Most frequent serious events
Most frequent serious events
EventBID Cohort: PlaceboBID Cohort: Rilzabrutinib 400 mg BIDTID Cohort: PlaceboTID Cohort: Rilzabrutinib 400 mg TID
Abscess LimbInfections and infestations0/180/271/310/48
Cutaneous T-Cell LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/180/270/311/48
Most frequent other events
Showing 10 of 102
Most frequent other events
EventBID Cohort: PlaceboBID Cohort: Rilzabrutinib 400 mg BIDTID Cohort: PlaceboTID Cohort: Rilzabrutinib 400 mg TID
NauseaGastrointestinal disorders0/188/271/3115/48
Dermatitis AtopicSkin and subcutaneous tissue disorders3/184/279/3115/48
DiarrhoeaGastrointestinal disorders0/184/270/3110/48
Covid-19Infections and infestations2/180/272/310/48
AcneSkin and subcutaneous tissue disorders1/180/273/310/48
ArthralgiaMusculoskeletal and connective tissue disorders0/180/270/314/48
NasopharyngitisInfections and infestations0/182/272/313/48
HeadacheNervous system disorders1/182/271/310/48
DyspnoeaRespiratory, thoracic and mediastinal disorders0/182/270/310/48
Blood Creatine Phosphokinase IncreasedInvestigations0/181/272/311/48

Baseline characteristics

Randomized population included all participants from screened population who had been allocated to a randomized intervention by interactive response technology (IRT) regardless of whether the intervention was received.

Age, Continuous
Age, Continuous(Years)BID Cohort: PlaceboBID Cohort: Rilzabrutinib 400 mg BIDTID Cohort: PlaceboTID Cohort: Rilzabrutinib 400 mg TIDTotal
Mean33.9 ± 13.038.3 ± 16.133.1 ± 12.436.1 ± 14.135.5 ± 14.0
Sex: Female, Male
Sex: Female, Male(Participants)BID Cohort: PlaceboBID Cohort: Rilzabrutinib 400 mg BIDTID Cohort: PlaceboTID Cohort: Rilzabrutinib 400 mg TIDTotal
Female1015153171
Male812161753
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BID Cohort: PlaceboBID Cohort: Rilzabrutinib 400 mg BIDTID Cohort: PlaceboTID Cohort: Rilzabrutinib 400 mg TIDTotal
American Indian or Alaska Native00000
Asian224614
Native Hawaiian or Other Pacific Islander00000
Black or African American01247
White16232538102
More than one race01001
Unknown or Not Reported00000
08

Study locations

31 sites
  • Antelope Valley Clinical Trials Site Number : 8400001
    Northridge, California 91325, United States
  • Asthma and Allergy Associates, PC Site Number : 8400008
    Colorado Springs, Colorado 80907, United States
  • Florida International Research Center Site Number : 8400002
    Miami, Florida 33173, United States
  • Skin Sciences, PLLC Site Number : 8400005
    Louisville, Kentucky 40217, United States
  • DS Research of Kentucky, LLC Site Number : 8400004
    Louisville, Kentucky 40241, United States
  • Integrative Skin Care of MS/SKYCRNG Site Number : 8400011
    Ridgeland, Mississippi 39157, United States
  • National Allergy and Asthma Research, LLC. Site Number : 8400007
    North Charleston, South Carolina 29420, United States
  • Orion Clinical Research Site Number : 8400003
    Austin, Texas 78759, United States
  • E.P.I.M.R.D dba Western Sky Research, Inc. Site Number : 8400009
    El Paso, Texas 79903, United States
  • Investigational Site Number : 1240008
    Red Deer, Alberta T4P 1K4, Canada
  • Investigational Site Number : 1240013
    Greater Sudbury, Ontario P3E 5M4, Canada
  • Investigational Site Number : 1240001
    London, Ontario N6A2C2, Canada
  • Investigational Site Number : 1240002
    Markham, Ontario L3P 1X3, Canada
  • Investigational Site Number : 1240011
    Toronto, Ontario M2N 3A6, Canada
  • Investigational Site Number : 1240007
    Toronto, Ontario M3H 5Y8, Canada
  • Investigational Site Number : 1240004
    Québec, G1V 4T3, Canada
  • Investigational Site Number : 1520004
    Santiago, Reg Metropolitana de Santiago 7580206, Chile
  • Investigational Site Number : 1520001
    Santiago, Reg Metropolitana de Santiago 7640881, Chile
  • Investigational Site Number : 1520002
    Santiago, Reg Metropolitana de Santiago 8420383, Chile
  • Investigational Site Number : 2030004
    Olomouc, 779 00, Czechia
  • Investigational Site Number : 2030003
    Pardubice, 53002, Czechia
  • Investigational Site Number : 2030002
    Pilsen, 30599, Czechia
  • Investigational Site Number : 2030001
    Prague, 160 00, Czechia
  • Investigational Site Number : 2760001
    Bad Bentheim, 48455, Germany
  • Investigational Site Number : 2760002
    Friedrichshafen, 88045, Germany
  • Investigational Site Number : 5280001
    Utrecht, 3584 CX, Netherlands
  • Investigational Site Number : 6160001
    Lodz, Lódzkie 90-436, Poland
  • Investigational Site Number : 6160005
    Gdansk, Pomeranian Voivodeship 80-546, Poland
  • Investigational Site Number : 6160008
    Chojnice, 89600, Poland
  • Investigational Site Number : 6160002
    Lodz, 93-530, Poland
  • Investigational Site Number : 6160004
    Warsaw, 00-215, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Jun 2023, 21 months.

Results were first posted in Jul 2026, 3 years after primary completion. A results delay was requested in Jun 2024.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 21 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2021
First posted
Aug 24, 2021
StartActual
Sep 9, 2021
Primary completionActual
Jun 23, 2023
CompletionActual
Jun 23, 2023
Results delay requested
Jun 20, 2024
Results first posted
Jul 13, 2026
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05018806
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 24, 2021
Start date
Sep 9, 2021
Primary completion
Jun 23, 2023
Completion
Jun 23, 2023
Results posted
Jul 13, 2026
Last update
Jul 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rilzabrutinib

Start the discussion